Using 16α-[18F]-Fluoro-17β-Estradiol PET to Visualize Estrogen Receptor α Expression in Human Breast Cancer Xenografts in Female Ovariectomized Mice
- Sadia Quazi 1, Nhi Huynh 2, Angela Rigopoulos 2, Alexander McDonald 3, Uwe Ackermann 4, Andrew Mark Scott 5, Ingrid Julienne Georgette Burvenich 6
- Sadia Quazi 1, Nhi Huynh 2, Angela Rigopoulos 2
- 1Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute; School of Cancer Medicine, La Trobe University.
- 2Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute.
- 3Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute; Department of Molecular Imaging and Therapy, Austin Health.
- 4Department of Molecular Imaging and Therapy, Austin Health.
- 5Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute; School of Cancer Medicine, La Trobe University; Department of Molecular Imaging and Therapy, Austin Health; Faculty of Medicine, The University of Melbourne.
- 6Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute; School of Cancer Medicine, La Trobe University; ingrid.burvenich@onjcri.org.au.
- 0Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute; School of Cancer Medicine, La Trobe University.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.16α-[18F]-fluoro-17β-estradiol (18F-FES) positron emission tomography (PET) can visualize estrogen receptor alpha (ERα) positive breast cancer xenografts. Optimal imaging requires tumors located away from the abdominal region to avoid obscuring by intestinal excretion.
Area Of Science
- Oncology
- Nuclear Medicine
- Radiochemistry
Background
- Estrogen receptor alpha (ERα) is a key target in breast cancer therapy.
- Positron emission tomography (PET) imaging offers a non-invasive method for visualizing biological processes.
- 16α-[18F]-fluoro-17β-estradiol (18F-FES) is a radiotracer designed to target ERα.
Purpose Of The Study
- To evaluate the efficacy of 18F-FES PET for visualizing ERα-positive breast cancer xenografts in mice.
- To determine the optimal tumor location for clear 18F-FES uptake detection in vivo.
- To assess the specificity of 18F-FES uptake in relation to ERα expression.
Main Methods
- ERα-positive (MCF-7) and ERα-negative (MDA-MB-231) breast cancer cells were implanted in BALB/c nude mice.
- Mice received 17β-estradiol to promote tumor growth, followed by a washout period before 18F-FES administration.
- PET/MRI imaging was performed 1-1.5 hours post-injection of 18F-FES.
Main Results
- 18F-FES uptake was observed in ERα-positive MCF-7 xenografts but not in ERα-negative MDA-MB-231 xenografts.
- Shoulder tumors showed clear 18F-FES uptake, while inguinal mammary fat pad tumors had less visible uptake.
- Intestinal excretion of 18F-FES interfered with imaging of tumors in the abdominal region.
Conclusions
- 18F-FES PET is a viable tool for visualizing ERα-positive breast cancer xenografts.
- Tumor location significantly impacts the clarity of 18F-FES imaging, with extra-abdominal sites being superior.
- Strategic placement of xenografts is crucial for successful application of 18F-FES PET in preclinical studies.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.